
    
      This was a randomized, double-blind, cross-over study of 4 treatments that was conducted
      according to the Good Clinical Practice Guidelines, with all applicable Food and Drug privacy
      regulations, and ethical principles based on the Declaration of Helsinki. Participants signed
      informed consent, approved by the Human Research Ethics Committee of the Endocrine-Metabolic
      Research Center of the University of Zulia, in Venezuela. All selected subjects attended a
      first visit, in order to determine if they met the inclusion criteria, those who gathered
      them, were subjected to four consumption tests to determine the glycemic index (GI) and
      glycemic load (GL) and 3 consumption tests for the evaluation of subjective appetite. Each
      treatment or consumption session was carried out on different days.
    
  